Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women’s Health (IMAGE)
Caption
This collaboration combines ASKA’s deep expertise in gynecological therapeutics with Insilico Medicine’s advanced AI-driven biological analytics capabilities to address major unmet medical needs affecting hundreds of millions of patients worldwide and to accelerate the development of innovative solutions. Under the partnership, Insilico will leverage PandaOmics to identify and explore disease hypotheses, while ASKA will validate the AI-predicted therapeutic targets with high translational potential.
Credit
Insilico Medicine
Usage Restrictions
None
License
Original content